NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 231 filers reported holding NEKTAR THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $19 | +35.7% | 15,500 | 0.0% | 0.00% | 0.0% |
Q1 2024 | $14 | +55.6% | 15,500 | 0.0% | 0.00% | 0.0% |
Q4 2023 | $9 | 0.0% | 15,500 | 0.0% | 0.00% | 0.0% |
Q3 2023 | $9 | 0.0% | 15,500 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $9 | -18.2% | 15,500 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $11 | -68.6% | 15,500 | 0.0% | 0.00% | -66.7% |
Q4 2022 | $35 | -99.9% | 15,500 | 0.0% | 0.00% | -40.0% |
Q3 2022 | $50,000 | -15.3% | 15,500 | 0.0% | 0.01% | -16.7% |
Q2 2022 | $59,000 | -29.8% | 15,500 | 0.0% | 0.01% | -14.3% |
Q1 2022 | $84,000 | -59.8% | 15,500 | 0.0% | 0.01% | -56.2% |
Q4 2021 | $209,000 | -62.5% | 15,500 | -50.0% | 0.02% | -66.0% |
Q3 2021 | $557,000 | +109.4% | 31,000 | +100.0% | 0.05% | +113.6% |
Q2 2021 | $266,000 | -14.2% | 15,500 | 0.0% | 0.02% | -24.1% |
Q1 2021 | $310,000 | +17.4% | 15,500 | 0.0% | 0.03% | +11.5% |
Q4 2020 | $264,000 | -37.6% | 15,500 | -39.2% | 0.03% | -43.5% |
Q3 2020 | $423,000 | -34.7% | 25,500 | -8.9% | 0.05% | -40.3% |
Q2 2020 | $648,000 | +29.6% | 28,000 | 0.0% | 0.08% | +5.5% |
Q1 2020 | $500,000 | -17.2% | 28,000 | 0.0% | 0.07% | +2.8% |
Q4 2019 | $604,000 | +18.4% | 28,000 | 0.0% | 0.07% | +10.9% |
Q3 2019 | $510,000 | -48.8% | 28,000 | 0.0% | 0.06% | -50.0% |
Q2 2019 | $996,000 | +5.8% | 28,000 | 0.0% | 0.13% | -2.3% |
Q1 2019 | $941,000 | +2.3% | 28,000 | 0.0% | 0.13% | -10.3% |
Q4 2018 | $920,000 | -74.0% | 28,000 | -51.7% | 0.15% | -69.5% |
Q3 2018 | $3,536,000 | +24.9% | 58,000 | 0.0% | 0.48% | +16.0% |
Q2 2018 | $2,832,000 | -54.0% | 58,000 | 0.0% | 0.41% | -55.3% |
Q1 2018 | $6,163,000 | +77.9% | 58,000 | 0.0% | 0.92% | +78.4% |
Q4 2017 | $3,464,000 | +148.9% | 58,000 | 0.0% | 0.52% | +127.2% |
Q3 2017 | $1,392,000 | +22.8% | 58,000 | 0.0% | 0.23% | +17.5% |
Q2 2017 | $1,134,000 | -16.7% | 58,000 | 0.0% | 0.19% | -19.2% |
Q1 2017 | $1,361,000 | +7.7% | 58,000 | -43.7% | 0.24% | +7.6% |
Q4 2016 | $1,264,000 | -28.6% | 103,000 | 0.0% | 0.22% | -30.7% |
Q3 2016 | $1,770,000 | +17.9% | 103,000 | -2.4% | 0.32% | +13.0% |
Q2 2016 | $1,501,000 | -3.7% | 105,500 | -6.9% | 0.28% | -7.5% |
Q1 2016 | $1,558,000 | -23.8% | 113,300 | -6.6% | 0.31% | -23.4% |
Q4 2015 | $2,044,000 | +63.3% | 121,300 | +6.1% | 0.40% | +62.1% |
Q3 2015 | $1,252,000 | -12.4% | 114,300 | 0.0% | 0.25% | -3.1% |
Q2 2015 | $1,430,000 | +13.7% | 114,300 | 0.0% | 0.26% | +11.3% |
Q1 2015 | $1,258,000 | -29.0% | 114,300 | 0.0% | 0.23% | -31.8% |
Q4 2014 | $1,771,000 | +28.3% | 114,300 | 0.0% | 0.34% | +28.6% |
Q3 2014 | $1,380,000 | -5.0% | 114,300 | +0.9% | 0.26% | -5.8% |
Q2 2014 | $1,453,000 | +5.8% | 113,300 | 0.0% | 0.28% | +1.1% |
Q1 2014 | $1,373,000 | +6.8% | 113,300 | 0.0% | 0.28% | +5.8% |
Q4 2013 | $1,286,000 | +8.2% | 113,300 | -0.4% | 0.26% | -2.6% |
Q3 2013 | $1,188,000 | -15.9% | 113,800 | -7.0% | 0.27% | -23.1% |
Q2 2013 | $1,413,000 | – | 122,300 | – | 0.35% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rhenman & Partners Asset Management AB | 1,350,000 | $22,950,000 | 1.87% |
MAVERICK CAPITAL LTD | 6,655,625 | $113,146,000 | 1.81% |
Camber Capital Management LP | 2,500,000 | $42,500,000 | 1.49% |
Bellevue Group AG | 3,866,258 | $65,726,000 | 0.75% |
Adero Partners, LLC | 51,500 | $876,000 | 0.75% |
Goodman Financial Corp | 108,342 | $1,842,000 | 0.64% |
CM Management, LLC | 35,000 | $595,000 | 0.55% |
OSTERWEIS CAPITAL MANAGEMENT INC | 424,504 | $7,217,000 | 0.43% |
RICE HALL JAMES & ASSOCIATES, LLC | 568,379 | $9,662,000 | 0.34% |
Burleson & Company, LLC | 107,736 | $1,832,000 | 0.32% |